
    
      A phase III, multicenter, single-arm, open-label study to assess the safety, tolerability and
      antiviral activity of DAG181/SOF combination for 12 weeks in adult subjects with chronic
      genotype 1 HCV infection.

      Approximately 360 HCV genotype 1 subjects without cirrhosis will be enrolled,
      treatment-experienced subjects are ≤20%. All subjects will receive DAG181 100 mg/ SOF 400 mg
      once daily for 12 weeks，with subsequent observation for 24 weeks after cessation of
      treatment.
    
  